Form 4: Artiva Biotherapeutics' Chief Medical Officer Receives 20,000 Restricted Stock Units

Thorsten Graef, Chief Medical Officer of Artiva Biotherapeutics, was granted 20,000 restricted stock units on September 12, 2024, under the company's 2024 Equity Incentive Plan.

Summary

• On September 12, 2024, Thorsten Graef, the Chief Medical Officer of Artiva Biotherapeutics, received 20,000 shares of common stock in the form of restricted stock units.
• The grant was made under the Issuer's 2024 Equity Incentive Plan.
• Following this transaction, Mr. Graef directly owns 20,000 shares of Artiva Biotherapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively. It indicates alignment of management interests with shareholders.

Positives

• The grant of restricted stock units to the Chief Medical Officer aligns his interests with those of the shareholders.
• The equity incentive plan is designed to attract and retain key employees.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives. This aligns management's interests with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• Many comparable biotechnology companies, such as Amgen and Gilead Sciences, utilize equity-based compensation plans to incentivize their executives.
• Restricted stock units are a standard component of these compensation packages, offering executives a stake in the company's future performance.
• The size of the grant is typical for a Chief Medical Officer in a company of Artiva Biotherapeutics' size and stage of development.

Stakeholder Impact

• Shareholders may view the equity grant positively as it aligns management's interests with the company's performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates